CFSAN Addresses AER Duplication, NDI Definition In Developing Guidances
This article was originally published in The Tan Sheet
Executive Summary
FDA is working on a method to avoid duplication when tracking adverse event reports, according to the director of CFSAN's Division of Dietary Supplement Programs